

# HEALTHY U CHIP

## PRIOR AUTHORIZATION REQUEST FORM

### CROHN'S DISEASE MEDICATIONS

Avsola®, Cimzia®, Entyvio®, Hadlima™, Humira®, Inflectra®, infliximab,  
Remicade®, Renflexis®, Rinvoq®, Skyrizi®, Stelara®

**For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department.**

- For **Medical Pharmacy** please fax requests to: 801-213-1547
- For **Retail Pharmacy** please fax requests to: 385-425-4052

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have prior authorization questions, please call for Pharmacy Customer Service for assistance at 385-425-5094

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

**Member must try formulary preferred drugs before a request for a non-formulary drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

#### Preferred/Non-Formulary:

**1. 1st Line Preferred Agents:**

- A. Hadlima™ (adalimumab-bwwd)
- B. Infliximab products: Avsola® (infliximab-axxq), Inflectra® (infliximab-dyyb), infliximab, Remicade (infliximab), Renflexis® (infliximab-abda)

**2. 2nd line preferred agents with single step; after trial and failure of BOTH Hadlima and a preferred infliximab agent:**

- A. Cimzia® (certolizumab), Entyvio® (vedolizumab) IV, Humira® (adalimumab)

**3. Non-Formulary agents with a triple step; after trial and failure of BOTH Hadlima and a preferred infliximab agent and Entyvio:**

- A. Rinvoq® (upadacitinib), Skyrizi® (risankizumab-rzaa), Stelara® (ustekinumab)

**4. Non-Formulary Agent after trial and failure of all the above:**

- A. Entyvio® (vedolizumab) subcutaneous injection

Product being requested: \_\_\_\_\_

Dosing/Frequency: \_\_\_\_\_

#### If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Is the request being made by or in consultation with a gastroenterologist?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does documentation include results from studies such as colonoscopy, MRI, CT scan?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

3. Does the member have severe Crohn's Disease evidenced by at least one of the following: <ul style="list-style-type: none"> <li>• A Crohn's Disease Activity Score (CDAI) &gt;220 AND as shown on imaging</li> <li>• Active fistulizing disease</li> </ul>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Does the member have moderate to severe Crohn's Disease evidenced by the following: <ul style="list-style-type: none"> <li>• Persistent fistulizing disease or active ulcerative disease as shown on imaging and via CDAI &gt; 150 despite an adequate trial with an immunomodulating medication such as methotrexate, azathioprine or 6-mercaptopurine, unless contraindicated to all.</li> </ul>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
5. Has the provider performed tuberculosis (TB) screening prior to therapy initiation?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
6. If the request is for a Tumor Necrosis Factor Inhibitor, has the provider performed hepatitis B screening prior to therapy initiation?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>REAUTHORIZATION</b>			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does documentation show a stabilization or decrease in the CDAI score of at least 70 points compared to baseline, endoscopic improvement in mucosa and/or no new fistulizing disease information?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has the provider performed continued tuberculosis monitoring during therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Has the provider performed continued Hepatitis B monitoring in HBV carriers?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician Signature:			

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request. \*\***

Policy: PHARM-CHIP-019  
Origination Date: 07/01/2024  
Reviewed/Revised Date:  
Next Review Date:  
Current Effective Date: 07/01/2024

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.